Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Faron Pharmaceuticals Oy (FRA:4FR) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Faron Pharmaceuticals Oy's Enterprise Value for the quarter that ended in Dec. 2025 was €261.75 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-25.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faron Pharmaceuticals Oy EV-to-EBIT Related Terms
Faron Pharmaceuticals Oy EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4FR vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Faron Pharmaceuticals Oy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Faron Pharmaceuticals Oy EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Faron Pharmaceuticals Oy's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Faron Pharmaceuticals Oy's EV-to-EBIT falls into.
Faron Pharmaceuticals Oy's current Enterprise Value is €109.76 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Faron Pharmaceuticals Oy's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-25.99 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Faron Pharmaceuticals Oy (FRA:4FR) has a EV-to-EBIT of -4.22 as of Aug. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Faron Pharmaceuticals Oy and its competitors. According to the industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 368 companies in the Biotechnology industry.
Is Faron Pharmaceuticals Oy's EV-to-EBIT too high?
Faron Pharmaceuticals Oy's current EV-to-EBIT is -4.22. Based on the distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 368 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Faron Pharmaceuticals Oy has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Faron Pharmaceuticals Oy's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Faron Pharmaceuticals Oy ranks #999999 out of 368 companies for EV-to-EBIT. This places Faron Pharmaceuticals Oy in the lower half of its industry. The industry median EV-to-EBIT is 15.71. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.71, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Faron Pharmaceuticals Oy and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Faron Pharmaceuticals Oy's current EV-to-EBIT is -4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Faron Pharmaceuticals Oy stock overvalued right now?
Faron Pharmaceuticals Oy (FRA:4FR) has a current EV-to-EBIT of -4.22. The current EV-to-EBIT is -4.22. Faron Pharmaceuticals Oy's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Faron Pharmaceuticals Oy (FRA:4FR), the current EV-to-EBIT is -4.22 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
32GF Score
Get the complete analysis for FRA:4FR
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4FR has been successfully added to your 
